Managing gestational trophoblastic neoplasm (GTN) and people living with HIV (PLWH)
The 2017 World Health Organization (WHO) global report on HIV/AIDS estimated that sub-Saharan Africa comprised 64% of the global HIV burden, with a current estimate of 19.4 million cases in Eastern and Southern Africa. Since the introduction of antiretroviral therapy (ART) there has been a 30–40% increase in the incidence of non-AIDS malignancies. Gestational trophoblastic disease comprises of a spectrum of pregnancy-related disorders with an overall cure rate of 90%. The response to treatment is generally favourable but the associated complications of HIV, comorbidities, poor performance status and extent of metastatic disease in gestational trophoblastic neoplasm patients receiving chemotherapy, compromises the outcome and survival.